MIRA Pharmaceuticals (NASDAQ:MIRA) Trading Up 6.2% – Here’s What Happened

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) traded up 6.2% during trading on Wednesday . The stock traded as high as $1.22 and last traded at $1.20. 249,482 shares were traded during mid-day trading, a decline of 25% from the average session volume of 332,859 shares. The stock had previously closed at $1.13.

MIRA Pharmaceuticals Stock Performance

The stock has a 50-day moving average price of $1.19 and a two-hundred day moving average price of $1.48. The stock has a market capitalization of $19.05 million, a PE ratio of -2.05 and a beta of 2.11.

MIRA Pharmaceuticals (NASDAQ:MIRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. As a group, equities analysts predict that MIRA Pharmaceuticals, Inc. will post -0.6 earnings per share for the current year.

Insider Activity at MIRA Pharmaceuticals

In other news, CEO Erez Aminov sold 55,410 shares of MIRA Pharmaceuticals stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $1.39, for a total transaction of $77,019.90. Following the sale, the chief executive officer now owns 1,105,790 shares in the company, valued at $1,537,048.10. This trade represents a 4.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 6.65% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On MIRA Pharmaceuticals

An institutional investor recently bought a new position in MIRA Pharmaceuticals stock. International Assets Investment Management LLC acquired a new stake in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $29,000. International Assets Investment Management LLC owned about 0.15% of MIRA Pharmaceuticals as of its most recent SEC filing. Institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.